Canadian researchers found that patients with immune-mediated inflammatory diseases (IMIDs) don’t face a heightened risk of venous thromboembolism events after recovering from COVID-19 compared to those without IMIDs. However, certain comorbidities can influence this risk, emphasizing the importance of individualized patient care.